Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 2/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 9/20 | 0.36 |
| ▸ | PIM1 | P11309 | 3/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.33 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21237241 | 0.86 | CREBBP (0.43) | CREBBPHTR3ASOS1PIM1PIM3 | |
| SCHEMBL21237355 | 0.83 | HTR3A (0.40) | CREBBPHTR3ASOS1 | |
| SCHEMBL19662814 | 0.82 | CREBBP (0.44) | CREBBPHTR3ASOS1PIM1PIM3 | |
| SCHEMBL21237245 | 0.82 | HTR3A (0.46) | CREBBPHTR3ASOS1 | |
| SCHEMBL21237242 | 0.81 | HTR3A (0.44) | CREBBPHTR3ASOS1 | |
| SCHEMBL21237243 | 0.81 | CREBBP (0.43) | CREBBPHTR3A | |
| SCHEMBL21237247 | 0.81 | CREBBP (0.43) | CREBBPHTR3A | |
| SCHEMBL21237473 | 0.80 | HTR3A (0.61) | HTR3ASOS1 | |
| SCHEMBL21237388 | 0.80 | CREBBP (0.46) | CREBBPHTR3ASOS1LRRK2 | |
| SCHEMBL19662985 | 0.80 | CREBBP (0.40) | CREBBPHTR3APIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-11247989-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247989-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, CREBBP | CREBBP 3/4885HTR3A 3917/4885SOS1 3470/4885 |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | CREBBP 3/4885HTR3A 3917/4885SOS1 3470/4885 |
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | CREBBP 3/4885HTR3A 3917/4885SOS1 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.